These findings lay the groundwork for combinatorial therapeutic strategies targeting Rho kinase, JAK–STAT, and WNT/β-catenin pathways—offering new hope for robust, durable repigmentation in vitiligo and related autoimmune dermatoses. This evidence concerns the gene SOAT1 and vitiligo.